樂
樂觀
樂觀 · 25%MAZE
$21.54
情境價格
$32.450
+3.005 (+9.26%)收盤時
Loading chart…
- 最高
- 32.610
- 開盤
- 29.820
- 成交量加權均價
- 31.55
- 成交量
- 1.57M
- 市值
- —
- 最低
- 29.581
- 成交金額
- 49.51M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- -26.39
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
AI 分析 of Maze Therapeutics Inc (MAZE)
買進Maze Therapeutics is a good buy right now, as it is currently priced at $27.53, with a forward P/E of 8.53, indicating potential undervaluation. The RSI is at 61.38, suggesting bullish momentum, and analysts project significant upside with targets of $50 and $64. However, the main risk is the recent insider stock sale by the Chief Medical Officer, which may indicate concerns about the company's future prospects.
估值指標
Maze Therapeutics Inc（MAZE）目前預期本益比為 8.53，5 年平均預期本益比為 1.45。
Alphio AI 對 MAZE 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
持有 MAZE 的大戶
事件時間軸
資訊
MAZE 常見問題 —— 由 Alphio AI 解答
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target. It operates in the Healthcare sector.
Maze Therapeutics is a good buy right now, as it is currently priced at $27.53, with a forward P/E of 8.53, indicating potential undervaluation. The RSI is at 61.38, suggesting bullish momentum, and analysts project significant upside with targets of $50 and $64. However, the main risk is the recent insider stock sale by the Chief Medical Officer, which may indicate concerns about the company's future prospects.
社群
更多 ↗暫無貼文
註冊或登入後參與討論本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。